18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer.

Tuulia ValliusJohanna HynninenJukka KemppainenVictor AlvesKari AuranenJaakko MatomäkiSinikka OksaJohanna VirtanenSeija GrénmanAnnika AuranenMarko Seppänen

Published in: European journal of nuclear medicine and molecular imaging (2018)

18F-FDG-PET/CT is helpful in NACT response evaluation. Patients with total MTV reduction <85% during NACT might be candidates for second-line chemotherapy and clinical trials, instead of interval debulking surgery.

Keyphrases

neoadjuvant chemotherapy
locally advanced
clinical trial
rectal cancer
lymph node
sentinel lymph node
minimally invasive
squamous cell carcinoma
radiation therapy
coronary artery bypass
surgical site infection
coronary artery disease
phase ii
randomized controlled trial
early stage
study protocol